Long-Term Safety Outcomes of Fecal Microbiota Transplantation: Real-World Data Over 8 Years From the Hong Kong FMT Registry
Clinical Gastroenterology and Hepatology · 2024-03 · 22 (3) · 611-620.e12
DOI: 10.1016/j.cgh.2023.09.001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2024-03. Verfasst von Yuk Kam Yau und 12 weiteren Autor:innen. Beteiligte Einrichtung: Microbiota I-Center, Hong Kong SAR, China; Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Hong Ko…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Clostridioides difficile, Clostridium Infections. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: Government of the Hong Kong Special Administrative Region of the People.
Abstract (Originalsprache)
BACKGROUND AND AIMS: Prospective long-term real-world safety data after fecal microbiota transplantation (FMT) remain limited. We reported long-term outcomes of FMT from a population-based FMT registry in Hong Kong. METHODS: We recruited patients undergoing FMT for recurrent Clostridioides difficile infection (CDI) and non-CDI indications from clinical trials, from June 2013 to April 2022 in Hong Kong. We captured data on demographics, FMT indications and procedures, clinical outcomes and short- to long-term safety. New medical diagnoses were obtained from electronic medical records and independently adjudicated by clinicians. Long-term safety in patients with recurrent CDI was compared with a control group treated with antibiotics. RESULTS: Overall, 123 subjects (median age 53 years, range 13-90 years; 52.0% male) underwent 510 FMTs and were prospectively followed up for a median of 30.3 (range, 1-57.9) months. The most common indication for FMT was type 2 diabetes mellitus. The most common short-term adverse events within 1 month of FMT included diarrhea and abdominal pain. At long-term follow-up beyond 12 months, 16 patients reported 21 new-onset medical conditions confirmed by electronic medical records. All were adjudicated to be unlikely to be related to FMT. There was no new case of inflammatory bowel disease, irritable bowel syndrome, allergy, diabetes mellitus, or psychiatric disorder. In a subgroup of patients with recurrent CDI, FMT was associated with a significantly higher cumulative survival probability compared with matched control subjects. CONCLUSIONS: This prospective real-world data from Asia's first FMT registry demonstrated that FMT has an excellent long-term safety profile. The risk of developing new medical conditions beyond 12 months after FMT is low.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Microbiota I-Center, Hong Kong SAR, China; Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China; Center for Gut Microbiota Research, Faculty of Medicine…
- Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China; Center for Gut Microbiota Research, Faculty of Medicine, The Chinese University of Hong Kong, Hong…
- Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.
- Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.
- Center for Gut Microbiota Research, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China; Department of Microbiology, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong SAR, China.
- Department of Gastroenterology, St Vincent's Hospital and University of Melbourne, Melbourne, Australia; Department of Medicine, St Vincent's Hospital and University of Melbourne, Melbourne, Australia.
Förderung
- Government of the Hong Kong Special Administrative Region of the People
Zitieren
APA
Yau, Y. K., Lau, L. H. S., Lui, R. N. S., Wong, S. H., Guo, C. L., Mak, J. W. Y., Ching, J. Y. L., Ip, M., Kamm, M. A., Rubin, D. T., Chan, P. K. S., Chan, F. K. L., & Ng, S. C. (2024). Long-Term Safety Outcomes of Fecal Microbiota Transplantation: Real-World Data Over 8 Years From the Hong Kong FMT Registry. Clinical Gastroenterology and Hepatology, 22(3), 611-620.e12. https://doi.org/10.1016/j.cgh.2023.09.001
Vancouver
Yau YK, Lau LHS, Lui RNS, Wong SH, Guo CL, Mak JWY, et al. Long-Term Safety Outcomes of Fecal Microbiota Transplantation: Real-World Data Over 8 Years From the Hong Kong FMT Registry. Clinical Gastroenterology and Hepatology. 2024;22(3):611-620.e12. doi:10.1016/j.cgh.2023.09.001
BibTeX
@article{Yau2024,
author = {Yau, Yuk Kam and Lau, Louis Ho Shing and Lui, Rashid Nok Shun and Wong, Sunny Hei and Guo, Cosmos Liutao and Mak, Joyce Wing Yan and Ching, Jessica Yuet Ling and Ip, Margaret and Kamm, Michael A and Rubin, David T and Chan, Paul Kay Sheung and Chan, Francis Ka Leung and Ng, Siew Chien},
title = {Long-Term Safety Outcomes of Fecal Microbiota Transplantation: Real-World Data Over 8 Years From the Hong Kong FMT Registry},
journal = {Clinical Gastroenterology and Hepatology},
year = {2024},
volume = {22},
number = {3},
pages = {611--620.e12},
doi = {10.1016/j.cgh.2023.09.001}
}
EUVIMED